← Back to catalogue
Research draft

bladder cancer

vr.tr.bladder-cancer · XCT.STA

Let an agent explain bladder cancer and its types in general terms from urology and oncology guidelines, describe risk factors, symptoms, diagnosis and treatment approaches, and route personal questions to clinicians.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain bladder cancer and its types in general terms from urology and oncology guidelines, describe risk factors, symptoms, diagnosis and treatment approaches, and route personal questions to clinicians.

Cancer arising in the urinary bladder, chiefly urothelial carcinoma in papillary and flat forms including flat intraepithelial lesions, ranging from non-muscle-invasive tumours managed by resection and intravesical therapy to muscle-invasive disease requiring cystectomy or chemoradiation, with rarer types such as urachal carcinoma, squamous and small cell carcinomas and inflammatory myofibroblastic tumours, and sites such as the lateral wall and bladder neck; smoking and occupational chemicals are major risk factors, and blood in the urine is the main warning sign.

What it is for: Not applicable; a cancer.

It can be explain types and risk factors; relay symptoms and diagnosis; relay treatment approaches; route personal questions.

Distinguishing features

Urothelial origin

Smoking as main risk

High recurrence

Stage-dependent treatment

What it looks like

Not a visible object; tumours seen at cystoscopy.

Physical character

new cases worldwide: about 610000 per year - GLOBOCAN 2022

non-muscle-invasive share: about 75 percent - at diagnosis

How it is recognised

Malignant tumour of the bladder

Urothelial carcinoma, papillary and flat lesions, rare types, sites

Benign bladder tumours and papillomas are not cancer; kidney and prostate cancers are separate

Related models

is a kind of - in registry terms

bladder neoplasm

is a kind of - in registry terms

urinary system cancer

is diagnosed by - with biopsy

cystoscopy

is caused by - as the main risk factor

tobacco smoking

In practice

Families and kinds

non-muscle-invasive urothelial carcinoma including papillary tumours and carcinoma in situ

muscle-invasive urothelial carcinoma

urachal carcinoma

squamous cell and small cell carcinoma of the bladder

rare tumours such as inflammatory myofibroblastic tumour

cancers by site such as lateral wall and bladder neck

Identifiers

ICD-11 2C94 malignant neoplasms of bladder

MeSH D001749 urinary bladder neoplasms

Standards and regulation

EAU, NCCN and other urology and oncology guidelines

Occupational exposure rules for bladder carcinogens

Cancer registration standards

Failure modes and hazards

Ignored haematuria

Agents giving personal medical advice

Recurrence without surveillance

Confusing types and stages

Also called

bladder papillary transitional cell neoplasmbladder flat intraepithelial lesionbladder urachal carcinomabladder inflammatory myofibroblastic tumorbladder lateral wall cancerbladder neck cancerurinary bladder posterior wall cancerurinary bladder anterior wall cancerbladder dome cancerbladder lymphomarecurrent malignant bladder neoplasmurachal cancerbladder urachal squamous cell carcinomabladder urachal urothelial carcinoma

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Help Getting help first.

Safety.

Signs

Warning signs.

Signs

Signs.

  1. Why does blood in the urine need prompt assessment, and what other signs matter? action
  2. Is the user describing such signs, which need a clinician promptly? boundary

Care

Specialist care.

Care

Care.

  1. How is bladder cancer diagnosed and staged by urologists, in general terms? provenance
  2. Is the user asking about their own diagnosis, which needs their care team? boundary
Understand The cancer.

Clinical.

Types

Types and stages.

Types

Types.

  1. What types and stages of bladder cancer exist? definition
  2. Is the question about bladder cancer or another urinary cancer? boundary

Risk

Risk factors.

Risk

Risk.

  1. What risk factors, including smoking and occupational exposures, does research identify? provenance
  2. Which entry fits the specific type? action
Treat Treatment.

Clinical.

Treatment

Treatment.

Treatment

Treatment.

  1. What treatments do guidelines recommend for non-muscle-invasive and muscle-invasive disease, in general terms? provenance
  2. Which references are standard? provenance

Follow-up

Surveillance and living.

Follow-up

Follow-up.

  1. How is recurrence monitored, and what support exists after cystectomy? provenance
  2. Which entry fits urinary diversion? action
Context Prevention and research.

Context.

Prevention

Prevention.

Prevention

Prevention.

  1. What prevention and occupational protections reduce bladder cancer, with sources? provenance
  2. Which sources are cited? provenance

Research

Research.

Research

Research.

  1. What research is advancing immunotherapy, targeted therapy and biomarkers, with findings attributed? provenance
  2. Which entry fits oncology research? action

What the second pass must settle

  • Should urothelial carcinoma be the primary linked entry?
  • How should guidelines be linked?
  • The registry entry has merged aliases naming lesions, rare tumours and sites; should they be split off?